IODOSORB◊ Gama de apósitos con cadexómero de yodo al 0,9 %

La composición de doble acción ofrece una actividad antimicrobiana de amplio espectro,1,2 con eliminación de esfacelo3,4 y altas propiedades de gestión de fluidos,5-7 lo que lo hace eficaz contra biofilm de heridas crónicas tanto in vitro como in vivo8-18

Prepárese para progresar

La tecnología inteligente de microesferas está cargada con yodo elemental al 0,9 % para ofrecer una liberación sostenida cuando el apósito está en contacto con el exudado de la herida.19-21

Se comercializa como pomada IODOSORB, polvo IODOSORB*.

Características del producto

IODOSORB MOA Video

Evidencias y casos de estudio

Tecnologías relacionadas

Medical Education

No results.

Información para el cliente

*Consulte la disponibilidad de cada producto de la gama IODOSORB en su país o región.

Citations
  1. Smith + Nephew 2018.Antimicrobial activity of IODOSORB range against a broad spectrum of wound pathogens. Internal Report. 1801001.
  2. Smith & Nephew 2018.Antimicrobial activity of IODOSORB range in a 3 day repeat challenge model. Internal Report. 1801002.
  3. Hansson C, Persson L-M, Stenquist B, et al. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. International Journal of Dermatology. 1998;37(390-396).
  4. Smith + Nephew 2007.An evaluation of the use of IODOSORB ointment and dressing in the management of chronic exuding wounds. Internal Report. SR/CE/027/IOD.
  5. Smith + Nephew 2017.Review of Perstorp Pharma Absorption Capacity Quality Assurance Data for IODOSORB/IODOFLEX Dressings. Internal Report. DS/17/365/R.
  6. Smith + Nephew 2017.Review of Perstorp Pharma Absorption Capacity Quality Assurance Data for IODOSORB Powder. Internal Report. DS/17/363/R.
  7. Smith + Nephew 2017.Review of Perstorp Pharma Absorption Capacity Quality Assurance Data for IODOSORB Ointment/Gel. DS/17/364/R.
  8. Fitzgerald DJ, Renick PJ, Forrest EC, et al. Cadexomer iodine provides superior efficacy against bacterial wound biofilms in vitro and in vivo. Wound Repair Regen. 2017;25(1):13-24.
  9. Smith & Nephew 2008.IODOFLEX dressings - disruption of a variety of micro-organisms grown in pre-established single and mixed species biofilms. Internal Report. 0804007.
  10. Roche ED, Woodmansey EJ, Yang Q, et al. Cadexomer iodine effectively reduces bacterial biofilm in porcine wounds ex vivo and in vivo. Int Wound J. 2019;1-10 [in press].
  11. Phillips PL, Yang Q, Davis S, et al. Antimicrobial dressing efficacy against mature Pseudomonas aeruginosa biofilm on porcine skin explants. Int Wound J. 2015;12(4):469-483.
  12. Schultz G, Qingpin Y. Microbicidal Effedts of Three Daily Treatments of a Carboxymethylcellulose Silver Dressing or a Cadexomer Iodine on Mature Bactericidal Biofilms Grown on Pig Skin Explants. 2016; Florence.
  13. Schultz G, Bjarnsholt T, James GA, et al. Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Repair Regen. 2017;25(5):744-757.
  14. Lantis J.C. Cadexomer Iodine on a biofilm in diabetic foot ulcers: A Pilot study. Paper presented at: WUWHS; 2016; Florence.
  15. Oates JL, Phillips CD, Wolcott R, Woodmansey E. Effect of a Cadexomer Iodine Wound Dressing on a Chronic Wound Multi-Species Biofilm Model with Comparison to a Silver Hydrofiber Antibiofilm Dressing. Paper presented at: SAWC; 2016; Las Vegas, USA.
  16. Malone M, Johani K, Jensen SO, et al. Effect of cadexomer iodine on the microbial load and diversity of chronic non-healing diabetic foot ulcers complicated by biofilm in vivo. J Antimicrob Chemother. 2017;72(7):2093-2101.
  17. Forrest EC, Gunning P, Coleman D, Fitzgerald DJ. Cadexomer Iodine delivers rapid and sustained broad spectrum antimicrobial activity and substantial biofilm disruption and kill in a clinicall revelant wound model. Paper presented at: EWMA; 2019; Gothenburg, Sweden.
  18. Akiyama H, Oono T, Saito M, Iwatsuki K. Assessment of Cadexomer Iodine against Staphylococcus aureus Biofilm In vivo and In vitro Using Confocal Laset Scanning Microscopy. The Journal of Dermatology. 2004;31:529-534.
  19. Hesler B. Release of iodine from IODOSORB/IODOFLEX Dressing into 0.9% saline solution over a three day period. Smith&Nephew Data on File # DS.18.026.R. (2018).
  20. Hesler B. Release of iodine from IODOSORB Powder into 0.9% saline solution over a three day period. Smith&Nephew Data on File # DS.18.024.R. (2018).
  21. Hesler B. Release of iodine from IODOSORB Ointment into 0.9% saline solution over a three day period. Smith&Nephew Data on File # DS.18.025.R. (2018).
  22. Ormiston MC, Seymour MTJ, Venn GE, Cohen RI, Fox JA. Controlled trial of Iodosorb in chronic venous ulcers. British Medical Journal. 1985;291:308-310.
  23. Troeng T, Skog E, Arnesjo B, et al. A Randomised Multicentre Trial to Compare the Efficacy of Cadexomer Iodine and Standard Treatment in the Management of Chronic Venous Ulcers in Out-Patients. Stuttgart: Schattauer Verlag; 1983.
  24. Holloway GA, Johansen KH, Barnes RW, Pierce GE. Multicenter Trial of Cadexomer Iodine to Treat Venous Stasis Ulcer. The Western Journal of Medicine. 1989;151(1):35-38.
  25. Smith + Nephew 2017.IODOSORB Powder Wound Model Testing - 3 day cavity testing with ALLEVYN Gentle Border secondary dressing using horse serum at a flow rate modelling that of a moderately exuding wound. Internal Report. DS/17/249/R.
  26. Smith + Nephew 2017.IODOSORB Ointment / Gel Wound Model Testing - 3 day cavity testing with ALLEVYN Gentle Border secondary dressing using horse serum at a low rate modelling that of a moderately exuding wound. Internal Report. DS/17/572/R.
  27. Smith + Nephew 2017.IODOSORB / IODOFLEX Dressing Wound Model Testing - 3 day cavity testing with ALLEVYN Gentle Border secondary dressing using horse serum at a low rate modelling that of a moderately exuding wound. Internal Report. DS/17/247/R.

Title

Text

Explore